PharmaVision offers a comprehensive choice of high quality, insightful reports which identify key trends, future innovations, and growth opportunities. Our reports cover the life science arena including pharmaceuticals, healthcare, diagnostics, drug delivery, emerging R&D technologies and consumer nutrition.
The top 10 pharma companies have now reported 1Q12 and the picture is mixed. Abbott Labs, GlaxoSmithKline, Merck & Co., Sanofi and Roche reported low to mid-single digit growth whilst AstraZeneca, El Lilly, J&J, Novartis and Pfizer experienced flat to negative sales growth due to loss of exclusivity of leading brands and manufacturing issues. Meanwhile Amgen has actively expanded its generics portfolio through the acquistion of MN Pharma. For more details on the global pharma, biotech and life science markets see our featured report...
Chronic, non-healing wounds are a major problem in the West. Ageing, obesity and increasingly common underlying conditions, such as diabetes, are significant contributory factors and will remain pivotal drivers in the future growth of the wound care market. Malnutrition, particularly amongst elderly patients, is known to inhibit healing.
